Shares of Cardiff Oncology Inc. (CRDF) are up over 25% at $2.21 in premarket trading today, following a business update provided by the clinical-stage biotechnology company.
The company's lead drug candidate is Onvansertib, a PLK1 inhibitor, being evaluated in combination with standard-of-care (SoC) therapeutics in a range of cancers.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com